💼 Business 6h ago · Amy Feldman, Forbes Staff

Two Dozen-Plus Biotechs Went Public This Year—With More In The Works

Forbes
Forbes business coverage
View Channel →
Two Dozen-Plus Biotechs Went Public This Year—With More In The Works
Source ↗ 👁 0 💬 0
In this week’s edition of InnovationRx, the bumper crop of biotech IPOs, Isomorphic’s reported $40 billion valuation fundraise, and the impact of drugmakers’ gifts to doctors.

Comments (0)

Sign in to join the discussion

More Like This

Chip stocks are on pace to erase $1 trillion as AI selloff deepens
Quartz · 2h ago
10 best true crime podcasts right now, and the real cases behind them
Quartz · 2h ago
📰
Bank of America shares drop 8% after third-quarter revenue miss and regulatory penalty
Business News · 3h ago
Netflix to lay off 1,000 staff in steepest cuts since 2022
BBC News · 3h ago
Earnings call transcript: Havas posts steady Q3 2026 growth as stock slips
All News · 3h ago
European shares edge up after solid ASML results, healthcare gains
All News · 3h ago